IPO Year: 2022
Exchange: AMEX
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
424B5 - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
10-Q - MAIA Biotechnology, Inc. (0001878313) (Filer)
D - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos
New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)
SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)
SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)
CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in San Francisco, California January 13-15, 2025. Dr. Vitoc will also host one-on-one meetings with investors throughout the 3-day event. The live event will be followed by a virtual 2-day event on January 21-22, 2025. At the conference, Dr. Vitoc will discuss MAIA's recent clinical developments and targeted value-dr
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that two of the Company's independent directors, Ramiro Guerrero, JD, LL.M. and Stan V. Smith, Ph.D., purchased MAIA's common stock and warrants in each of the Company's recent private placement closings which occurred on November 1, 2024, and December 13, 2024. Total gross proceeds to MAIA from the closings were $3.4 million. Mr. Guerrero purchased a total of 141,952 shares and 141,952 warrants for an aggregate purchase price of approximately $300,000. Dr. Smith purchased a total of 125,000 shares and 125,000 warrants fo
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a "rare pediatric disease." "THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease," s
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 507,364 shares of common stock at a purchase price of $1.872 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.08 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to
Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next stage of trial to further assess efficacy of THIO in third line non-small cell lung cancer patients MAIA expects new patient enrollment to begin soon in the expansion of THIO-101 MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has amended the 2021 clinical supply agreement with Regeneron for the expansion portion of THIO-101, its Phase 2 clinical trial evaluating THIO in sequential administration with cemiplimab (Libtayo®). The new expansion will further assess the efficacy of M
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 100,000 shares of MAIA's common stock, and warrants to purchase 100,000 shares, of MAIA's common stock for an aggregate purchase price of $225,900 as part of the Company's recent private placement of common stock and warrants announced by the Company on October 28, 2024, and which closed on November 1, 2024. "As one of our original investors, Stan has participated in nearly every private placement financing round since our Company's inception. We
Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with cemiplimab beyond treatment cessation MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that a late-breaking abstract (LBA) detailing new updates from its Phase 2 THIO-101 clinical trial was selected for oral and poster presentation at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 6-10, 2024, in Houston, Texas. The updates will
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of common stock at a purchase price of $2.259 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.51 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject t
MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract related to the company's second generation of proprietary telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024, in Barcelona, Spain. The Symposium is hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI)
16 patients surpassed 12-month survival follow-up THIO's substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 months Median survival follow-up in third line was 10.6 months Treatment with THIO followed by Libtayo® has been generally well-tolerated to date MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer (NSCLC). A Phase 2 clinical trial, THIO-101, is evalu